NSG 5240 FINAL EXAM STUDY GUIDE
COMPREHENSIVE REVIEW FOR ADVANCED
PHARMACOLOGY & PATHOPHYSIOLOGY
EXAM OVERVIEW
Category Details
Course Code NSG 5240
Content Areas Advanced Pharmacology & Advanced Pathophysiology
Exam Format Multiple choice, select all that apply, case-based scenarios
Question Bank 150-180 questions
Passing Score 80% (typically)
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS (Core Concepts)
Key Pharmacokinetic Processes
Process Definition Clinical Implications
Movement from administration site IV = 100% bioavailability; oral affected
Absorption
to bloodstream first-pass effect
,Process Definition Clinical Implications
Movement throughout body Lipophilic drugs have large Vd; protein
Distribution
fluids/tissues binding affects free drug
Biotransformation (primarily liver - Impaired liver function increases drug
Metabolism
CYP450 system) levels
Renal impairment requires dose
Excretion Elimination (primarily kidneys)
adjustment
High-Yield Pharmacokinetic Questions
1. A patient with liver cirrhosis has reduced metabolism of a drug that normally
undergoes extensive first-pass effect. How will this affect the oral dose of the
drug?
Answer: Significantly increased bioavailability
Rationale: The first-pass effect occurs in the liver. Liver impairment means less
drug is metabolized before reaching systemic circulation, leading to higher
bioavailability and potential toxicity.
2. A drug has a half-life of 12 hours. How many hours will it take to reach steady
state?
Answer: 60 hours
*Rationale: Steady state is achieved after approximately 4-5 half-lives. 5 × 12
hours = 60 hours.*
3. Which route of administration bypasses the first-pass effect? (Select all that
apply)
Answer: Sublingual and Rectal
, Rationale: Sublingual and rectal administration allow absorption directly into
systemic circulation, partially or fully avoiding portal circulation and first-pass
metabolism in the liver.
4. A drug with a high volume of distribution (Vd) primarily indicates:
Answer: The drug extensively distributes into tissues
Rationale: A high Vd suggests the drug has left the plasma and entered tissues,
often due to lipophilicity or tissue binding. High protein binding usually decreases
Vd.
5. Which cytochrome P450 enzyme is most commonly involved in drug-drug
interactions?
Answer: CYP3A4
*Rationale: CYP3A4 metabolizes >50% of all drugs and is inhibited/induced by
many agents (e.g., grapefruit juice, rifampin, ketoconazole).*
6. Grapefruit juice increases levels of certain drugs by:
Answer: Inhibiting intestinal CYP3A4
*Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4, reducing first-
pass metabolism and increasing bioavailability.*
7. What is the primary clinical implication for an APRN when prescribing a drug
with a narrow therapeutic index?
Answer: There is a small margin between the effective and toxic dose
Rationale: For drugs like warfarin, digoxin, and phenytoin, the difference between
a therapeutic and a toxic concentration is small. Careful monitoring is essential.
8. A patient develops tolerance to morphine after chronic use. This is most likely
due to:
Answer: Receptor downregulation
COMPREHENSIVE REVIEW FOR ADVANCED
PHARMACOLOGY & PATHOPHYSIOLOGY
EXAM OVERVIEW
Category Details
Course Code NSG 5240
Content Areas Advanced Pharmacology & Advanced Pathophysiology
Exam Format Multiple choice, select all that apply, case-based scenarios
Question Bank 150-180 questions
Passing Score 80% (typically)
SECTION 1: PHARMACOKINETICS &
PHARMACODYNAMICS (Core Concepts)
Key Pharmacokinetic Processes
Process Definition Clinical Implications
Movement from administration site IV = 100% bioavailability; oral affected
Absorption
to bloodstream first-pass effect
,Process Definition Clinical Implications
Movement throughout body Lipophilic drugs have large Vd; protein
Distribution
fluids/tissues binding affects free drug
Biotransformation (primarily liver - Impaired liver function increases drug
Metabolism
CYP450 system) levels
Renal impairment requires dose
Excretion Elimination (primarily kidneys)
adjustment
High-Yield Pharmacokinetic Questions
1. A patient with liver cirrhosis has reduced metabolism of a drug that normally
undergoes extensive first-pass effect. How will this affect the oral dose of the
drug?
Answer: Significantly increased bioavailability
Rationale: The first-pass effect occurs in the liver. Liver impairment means less
drug is metabolized before reaching systemic circulation, leading to higher
bioavailability and potential toxicity.
2. A drug has a half-life of 12 hours. How many hours will it take to reach steady
state?
Answer: 60 hours
*Rationale: Steady state is achieved after approximately 4-5 half-lives. 5 × 12
hours = 60 hours.*
3. Which route of administration bypasses the first-pass effect? (Select all that
apply)
Answer: Sublingual and Rectal
, Rationale: Sublingual and rectal administration allow absorption directly into
systemic circulation, partially or fully avoiding portal circulation and first-pass
metabolism in the liver.
4. A drug with a high volume of distribution (Vd) primarily indicates:
Answer: The drug extensively distributes into tissues
Rationale: A high Vd suggests the drug has left the plasma and entered tissues,
often due to lipophilicity or tissue binding. High protein binding usually decreases
Vd.
5. Which cytochrome P450 enzyme is most commonly involved in drug-drug
interactions?
Answer: CYP3A4
*Rationale: CYP3A4 metabolizes >50% of all drugs and is inhibited/induced by
many agents (e.g., grapefruit juice, rifampin, ketoconazole).*
6. Grapefruit juice increases levels of certain drugs by:
Answer: Inhibiting intestinal CYP3A4
*Rationale: Grapefruit juice irreversibly inhibits intestinal CYP3A4, reducing first-
pass metabolism and increasing bioavailability.*
7. What is the primary clinical implication for an APRN when prescribing a drug
with a narrow therapeutic index?
Answer: There is a small margin between the effective and toxic dose
Rationale: For drugs like warfarin, digoxin, and phenytoin, the difference between
a therapeutic and a toxic concentration is small. Careful monitoring is essential.
8. A patient develops tolerance to morphine after chronic use. This is most likely
due to:
Answer: Receptor downregulation
